A new international study has found that a simple tablet treatment could improve survival rates for people with chronic ...

Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company focusing on precision oncology treatments, announced today that it has entered into financial agreements to potentially increase its capital.

Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing the tuspetinib (TUS)-based ...

Basophilia at diagnosis of myeloproliferative neoplasms was associated with a more aggressive disease phenotype and poorer ...

A research team from Osaka University investigates the impact of antioxidant enzymes on specific cell types and their role in ...

Cancer cells have special adaptation mechanisms that allow them to proliferate despite changes in their genetic makeup.

Shernan Holtan, MD, has been named the recipient of 2025 Lukas D. Wartman Award. Holtan, chief of blood and marrow ...

When a tumor develops, it creates a structure around itself called the tumor stroma, within which blood and lymphatic vessels ...

Companion Diagnostics Market Companion Diagnostics Market Dublin, Feb. 13, 2025 (GLOBE NEWSWIRE) -- The "Companion ...

Kuick Research Report Highlights Ongoing Developments In Molecular Switches Application Therapeutic Targets & Drug Delivery ...

Aptose Biosciences (NASDAQ:APTO;TSX:APS), a clinical-stage oncology stock, achieved positive safety and response results from ...

In January 2025, Aptose announced the initiation of the TUSCANY trial and dosing in the first cohort of newly-diagnosed AML patients with the lowest starting dose (40 mg) of TUS as part of the ...